Document is current
Any future updates will be listed below
-
Authors
Seifert, Nicole https://orcid.org/0000-0002-2191-523X
Reinke, Sarah https://orcid.org/0000-0001-9729-4030
Grund, Johanna
Müller-Meinhard, Berit
Richter, Julia https://orcid.org/0000-0002-9543-4084
Heilmann, Thorsten
Schlößer, Hans
Kotrova, Michaela
Brüggemann, Monika
Borchmann, Peter
Bröckelmann, Paul J. https://orcid.org/0000-0001-9662-9900
Altenbuchinger, Michael
Klapper, Wolfram https://orcid.org/0000-0001-7208-4117
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70112502)
International Max-Planck Research School for Genome Science
Adaptive Biotcehnologies, Young Investigator Award
Else Kröner-Fresenius-Stiftung (Excellence Stipend)
- License Information
-
More Information
Article History
Received: 14 August 2024
Revised: 21 November 2024
Accepted: 28 November 2024
First Online: 17 December 2024
COMPETING INTERESTS
: PB reports grants from BMS during the conduct of the study. No other disclosures were reported. PJB is an advisor or consultant for Merck Sharp & Dohme, Need Inc., Stemline, and Takeda; holds stock options in Need Inc., has received honoraria from BeiGene, BMS/Celgene, Merck Sharp & Dohme, Need Inc., Stemline and Takeda and reports research funding from BeiGene (Inst), BMS (Inst), Merck Sharp & Dohme (Inst) and Takeda (Inst); all outside the submitted work. WK reports grants from Roche, Amgen, Takeda, inCyte, and Regeneron paid to his institution not related to the submitted work. No other potential conflicts of interest are reported. TH received honoraria from Amgen, Astra Zeneca, Daiichi Sankyo, Exact Sciences, Gilead, Lilly, MSD, Novartis, Roche, Serag Wiessner, and travel support from Gilead.
: All methods were performed in accordance with the relevant guidelines and regulations. Approval has been obtained from the ethics advisory committee of the Medical Faculty of the University of Kiel (D464/17). Informed consent was obtained from all participants of the NIVAHL trial.
